This study is being conducted to evaluate if the study drug, Rosuvastatin, is safe and can help people living with cirrhosis lead longer, healthier lives.

This study drug has been approved by the U.S. Food and Drug Administration (FDA) to treat individuals with high cholesterol but has not been approved to treat cirrhosis, which means it is investigational in this study. An investigational/experimental drug is one that is currently being tested and has not been approved by the FDA for sale in the United States or by any regulatory authorities in any country in the world. 
   
Participants in this study will take 1 tablet of rosuvastatin by mouth once a day for 4 weeks. 
   
Participation in this study will last approximately 2 years (24 months) and participants will be compensated for their time.